Call for applications for a fully financed PhD fellowship
Multiple myeloma (MM) is a bone marrow cancer of plasma cells with poor prognosis that affects 300 Danes per year. Novel immunotherapies have revolutionized the treatment landscape of the disease, including bispecific antibodies. Bispecific antibodies are antibodies that concomitantly target endogenous T cells and antigens presented on the myeloma cancer cell membrane, redirecting the patients´ own immune system to attack the disease. While bispecific antibodies are promising for treating patients with MM, a fraction of patients present poor response due to unknown mechanisms. In this project, we will apply advanced molecular histology, spatial transcriptomics and TCR sequencing to patient samples from the TALTEC clinical trial (newly diagnosed patients reciving sequencial bispecifics) to elucidate the mechanisms of treatment resistance.
The ideal candidate for this position is a motivated and pasionate scientist with experience in bioinformatics and, preferably, analyses of spatial transcriptomics datasets.
BSc, MSc.
Please submit your application via this link. Application deadline is 1 November 2026 23:59 local Danish time. Preferred starting date is 1 May 2027.
For information about application requirements and mandatory attachments, please see our application guide.
Please contact Assistant Professor Marta Diaz del Castillo, marta@forens.au.dk or Professor Thomas Levin Andersen, thomas.levin.andersen@rsyd.dk for more information.
All interested candidates are encouraged to apply, regardless of their personal background. Salary and terms of employment are in accordance with applicable collective agreement.
